Table 1 Correlation between the nuclear expression levels of MTA1 and the clinicopathological characteristics of nasopharyngeal carcinoma patients
Characteristic | No. of patients | MTA1 Nuclear Expression | Chi-square test | |
|---|---|---|---|---|
Low, n(%) | High, n(%) | P value | ||
Sex | 0.93 | |||
Male | 155 | 80 (51.6%) | 75 (48.4%) | |
Female | 53 | 27 (50.9%) | 26 (49.1%) | |
Age(y) | 0.86 | |||
≤ 50 | 129 | 67 (51.9%) | 62 (48.1%) | |
> 50 | 79 | 40 (50.6%) | 39 (49.4%) | |
T classification | 0.07 | |||
T1-T2 | 104 | 60 (57.7%) | 44 (42.3%) | |
T3-T4 | 104 | 47 (45.2%) | 57 (54.8%) | |
N classification | 0.02 | |||
N0-N1 | 130 | 75 (57.7%) | 55 (42.3%) | |
N2-N3 | 78 | 32 (41.0%) | 46 (59.0%) | |
Clinical stage | 0.04 | |||
I-II | 70 | 43 (61.4%) | 27 (38.6%) | |
III-IV | 138 | 64 (46.4%) | 74 (53.6%) | |
Locoregional failure | 0.61 | |||
No | 185 | 94 (50.8%) | 91 (49.2%) | |
Yes | 23 | 13 (56.5%) | 10 (43.5%) | |
Distant metastasis | <0.01 | |||
No | 159 | 90 (56.6%) | 69 (43.4%) | |
Yes | 49 | 17 (34.7%) | 32 (65.3%) | |
Death | 0.01 | |||
No | 160 | 90 (56.2%) | 70 (43.8%) | |
Yes | 48 | 17 (35.4%) | 31 (64.6%) | |